Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 18;9(2):003125.
doi: 10.12890/2022_003125. eCollection 2022.

Unintentional Dual Benefit: Improvement in Secondary Polycythemia in a Patient Receiving Chemotherapy for Metastatic Clear Cell Renal Cell Carcinoma

Brooke Kania  1 , Erinie Mekheal  1 , Sherif Roman  1 , Nader Mekheal  1 , Vinod Kumar  1 , Michael Maroules  1
Affiliations

Unintentional Dual Benefit: Improvement in Secondary Polycythemia in a Patient Receiving Chemotherapy for Metastatic Clear Cell Renal Cell Carcinoma

Brooke Kania et al. Eur J Case Rep Intern Med. .

Abstract

Complete blood counts are frequently collected from cancer patients, but laboratory findings may be misleading. Secondary polycythemia can occur in renal cell carcinoma (RCC) due to erythropoietin (EPO) stimulation. Therefore, complete blood counts should be closely monitored to prevent complications such as thrombosis. We discuss the case of a 47-year-old man with metastatic RCC who presented with secondary polycythemia that improved with chemotherapy. His secondary erythrocytosis was anticipated, but his haemoglobin levels were lower than expected after therapy. This article discusses the treatment and diagnosis of secondary polycythemia in patients with RCC.

Learning points: Haemoglobin and haematocrit levels should be closely monitored in renal cell carcinoma (RCC) patients as they may develop secondary polycythemia as a result of their malignancy.Secondary polycythemia can be managed with chemotherapy and immunotherapy in RCC, with anti-cancer agents preventing the need for phlebotomy.Chemotherapy may benefit RCC patients by decreasing tumour burden, preventing progression, and by lowering haemoglobin levels, thus improving secondary polycythemia.

Keywords: EPO-producing tumour; Metastatic renal cell carcinoma; everolimus; paraneoplastic syndrome; secondary polycythemia.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: The Authors declare that there are no competing interests.

Figures

Figure 1
Figure 1
Renal cell carcinoma (clear cell), optically clear cells with round, uniform nuclei (due to glycogen content), arranged in nests in ‘chicken wire’ vasculature, Grade 1. Sometimes, delicate capillaries rupture during surgical manipulation, resulting in the formation of ‘blood lakes’ within tumour cell nests. H&E stain
See this image and copyright information in PMC

References

    1. Ljungberg B, Rasmuson T, Grankvist K. Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker. Eur Urol. 1992;21:160–3. - PubMed
    1. Michael A, Politi E, Havranek E, Corbishley C, Karapanagiotou L, Anderson C, et al. Prognostic significance of erythropoietin expression in human renal cell carcinoma. BJU Int. 2007;100(2):291–4. - PubMed
    1. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol. 2002;4(4):163. - PMC - PubMed
    1. Murphy GP, Kenny GM, Mirand EA. Erythropoietin levels in patients with renal tumors or cysts. Cancer. 1970;26(1):191–4. - PubMed
    1. Janik JE, Sharfman WH, Smith JW, Longo DL, Sznol M, Urba WJ, et al. Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer. 1993;72(9):2656–9. - PubMed

LinkOut - more resources